Diurnal has received a £600,000 ($982,000) investment to further development of products using its drug delivery technology, which uses delayed and sustained release to mimic the body’s circadian rhythm.
Scientists have determined the precise molecular structure of a
potential new target for treating prostate cancer, a disease driven
in part by abnormal testosterone activity, which affects one in six
Debiopharm of Switzerland has won approval for a three-month depot
formulation of Pamorelin (triptorelin pamoate), a drug to treat
prostate cancer, based on its proprietary polymer-based drug